

Lenti-siRNA Expression Systems

iLenti-siRNA Vector	LV014
iLenti-siRNA-GFP Vector	LV016
Complete iLenti-siRNA Expression Kit	LV300
Complete iLenti-siRNA-GFP Expression Kit	LV301
Partial iLenti-siRNA Expression Kit	LV310
Partial iLenti-siRNA-GFP Expression Kit	LV311
Supplemental Kit for All Lentivirus Systems	LV098
Supplemental Kit for All Lentivirus Systems	LV099

Table of Contents

Notice to the Purchaser	1
Technical Support	1
Biosafety	2
Protocol at a Glance	3
Lenti-siRNA Expression System	5
General Information about Lentiviral Vectors	6
How Lentiviruses Work	6
VSV Glycoprotein Envelope	6
Packaging Limits	6
Materials	7
Additional Materials Required	7
Storage	7
Protocol	8
Designing siRNA Target Sequences	8
Subcloning Target Sequences into the iLenti Vector	9
Identification of iLenti Clones	10
Lentiviral Particle Production	10
293T Cells	11
Transfection Procedure	11
Concentrating Virus	13
Long Term Storage	13
Viral Titre Assays	13
Transduction Procedure	15
Troubleshooting	17
References	18
Contact Information	20

Notice to the Purchaser

The products are for research use only. Use in and/or for diagnostics or therapeutics is strictly prohibited. By opening and using the product, the purchaser agrees to the following: The components in this kit may not be distributed, resold, or modified for resale without prior written approval from Applied Biological Materials (**abm**) Inc. The information in this document is subject to change without notice and should not be construed as a commitment by **abm** Inc. or its affiliated corporations. In no event shall **abm** Inc. or its affiliated corporations be liable for incidental or consequential damages in connection with or arising from the use of this manual and product.

abm Inc. products are warranted to meet our QC testing standards at the time of shipment. Notice of problematic products must be made to **abm** Inc. within 15 days of receipt of the product. This product warranty limits **abm** Inc.'s liability to the replacement of the product only.

Technical Support

For more information on **abm** Inc. products, please visit our website:

<http://www.abmGood.com>

For additional information or technical assistance, please call or email us at:

Applied Biological Materials, Inc.

Phone: (604) 247-2416

1-866-757-2414

Fax: (604) 247-2414

E-mail: technical@abmGood.com

Biosafety

Our iLenti-siRNA Expression System employs 3rd generation self-inactivating recombinant lentiviral vectors with enhanced biosafety and minimal relation to the wild-type, human HIV-1 virus. The lentiviral particles produced with this system are replication-incompetent and designed with a number of safety features to enhance their biosafety.

All Lentiviral Expression Systems provided from abm Inc. include the following safety features:

- An enhancer deletion in the U3 region of 3' Δ LTR ensures self-inactivation of the lentiviral vector following transduction & integration into the target cell's genomic DNA.
- Utilization of a RSV promoter upstream of 5' Δ LTR allows efficient Tet-independent production of viral RNA.
- The number of lentiviral genes necessary for packaging, replication and transduction is limited to three (Gag/Pol/Rev), and their expression is derived from different plasmids, all lacking packaging signals. The plasmids share no significant homology to the expression vector, preventing the generation of replication-competent virus.
- None of the Gag, Pol, or Rev genes will be present in the packaged viral genome, thus making the mature virus replication-incompetent.

Despite the safety features discussed above, it is highly recommended that all manipulation with lentiviral vectors, including viral production and transduction, be performed under Biosafety Level 2 (BL-2). All published BL-2 guidelines with proper waste decontamination should be strictly followed. In addition, exercise extra caution when creating lentivirus carrying potentially harmful or toxic genes (e.g. oncogenes). For more information about the BL-2 guidelines and lentivirus handling, refer to "Biosafety in Microbiological and Biomedical Laboratories," 5th Edition. This may be downloaded at: www.cdc.gov/biosafety/publications/bmbl5/index.htm

It is also important to consult with the health and safety officer(s) at your institution for guidelines regarding the use of lentiviruses, and to always follow standard microbiological practices, which include:

- Wear gloves and a lab coat at all times.
- Always work with pseudoviral particles in a Class II culture facility and that all procedures are performed carefully to minimize splashes and aerosols.
- Work surfaces are decontaminated at least once a day and after any spills of viable material.
- All cultures, stocks and other regulated wastes are decontaminated before disposal by an approved decontamination method, like autoclaving.

Protocol at a Glance




Figure 1: Procedure for Transient Production of Pseudoviral Particles and Transduction of Target Cells.




Figure 2: Map of iLenti-siRNA & iLenti-siRNA-GFP Vectors

Small interfering RNA (siRNA), also known as short interfering RNA, is a class of 20-29 nucleotide, double-stranded RNA molecules that play a variety of roles in biological processes. siRNAs were initially discovered to be involved in the RNA interference (RNAi) pathway, silencing the expression of specific genes through post-transcriptional mechanisms (Fire et al. 1998). Recent studies demonstrate that siRNAs also act in other RNA related pathways, such as anti-viral mechanisms and shaping the chromatin structure in a genome. The complexity of these pathways has only recently been elucidated (Hawkins and Morris 2008).

Since the initial demonstration of its functionality in mammalian cells, siRNA technology has been an indispensable tool in functional genomics and is predicted to become a novel form of future medicine (Grünweller and Hartmann 2005).

abm's iLenti™ expression system is the most advanced lentiviral vector-based siRNA expression system, with improved features over other competing vector-based siRNA systems.

1) iLenti™ vectors are extremely stable and have the ability to grow in regular DH5a competent cells, eliminating the need for special, stable competent cells.

2) iLenti™ uses convergent promoters to avoid hairpin loop structure design. Cloned siRNA will therefore be less likely to form secondary structures, allowing easier plasmid propagation and sequencing.

3) The convergent promoter design also enables longer siRNA inserts of 27-29 bp oligos, which have been shown to be more efficient than traditional 21mers in specific gene knockdown (Kim et al. 2005).

4) iLenti™ significantly reduces the production cost of oligos. 33 bp inserts are used instead of the ~60bp oligos used by our competitors.

5) The iLenti™ Cloning Vector has a unique, single BbsI restriction enzyme site in the multiple cloning site, which allows efficient, directional cloning of siRNA target sites.

6) iLenti™ also has a GFP reporter gene incorporated under the CMV promoter, which allows simultaneous tracking of expressed siRNAs *in vitro* and *in vivo*.

Lenti-siRNA Expression System

General Information about Lentiviral Vectors

Morphology: Virions consist of an envelope, a nucleocapsid, a nucleoid, and matrix proteins. The enveloped virions assume a spherical to pleomorphic shape of 80-100nm in diameter. The virion surface is covered with dense inconspicuous spikes of 8 nm in length.

Physical Properties: Virions have a buoyant density of 1.13-1.18g/cm³ in sucrose. Virions are sensitive to treatment with heat, detergents, and formaldehyde. The infectivity is not affected by irradiation.

How siRNA Lentiviruses Work

Vector-based siRNAs are the method of choice for both transient and stable gene knockdown. Due to its high transduction efficiency, lentiviral vector-based siRNA is considered to be the most efficient delivery method available. By incorporating siRNA into lentiviral vectors, specific gene expression can be knocked-down by either plasmid transfection or lentiviral infection for any target cell. Another advantage of using lentiviral vector expressed siRNA is the efficient and stable expression of siRNA in both dividing and non-dividing cells, including even transfection-resistant cells such as primary cells.

VSV Glycoprotein Envelope

Most commercial retroviral vectors are limited in gene delivery applications because of their restricted tropisms and generally low titres. For recombinant lentiviral vectors, these limitations are resolved by pseudotyping the vector with the G glycoprotein gene from Vesicular Stomatitis Virus Glycoprotein (VSV-G) envelope. The significant advantages associated with the use of VSV-G envelope include:

- allowing production of high titre lentiviruses
- increasing viral particle stability
- broadening target cell ranges
- generating highly efficient transduction (Burns et al., 1993; Emi et al., 1991; Yee et al., 1987, 1994, 1999).

Packaging Limits

Recombinant lentiviral titres will decrease with increasing insert gene size. The packaging limit for our Lenti-siRNA expression system is approximately 5.5 kb; above these limits, little to no virus will be produced.

Materials

Scientists at **abm** have successfully developed a comprehensive product line for siRNA expression along with reagents for packaging viral particles. In addition, ready-to-use lentiviral particles are also available for immediate transduction of any target cells as in shown in Table I.

Table I. Lenti-siRNA Cloning Vectors and Kits

Component	Cat. #	Quantity	Kit Cat. No.					
			LV300	LV301	LV310	LV311	LV098	LV099
iLenti-siRNA Vector	LV014	10 µg	✓		✓			
iLenti-siRNA-GFP Vector	LV016	10 µg		✓		✓		
2nd Gen. Packaging Mix	LV003	100 µl	✓	✓	✓	✓		✓
Lentifectin™	G074	1.0 ml	✓	✓			✓	
293T Cells	LV010	1x10 ⁶	✓	✓				✓
Lenti-GFP Vector	LV011-a	10 µg	✓	✓				✓
Sequencing Primer	LV012	100 µl	✓	✓	✓	✓		

Additional Materials Required

The following materials and reagents are required but not provided:

- Dulbecco's Modified Eagle's Medium (Invitrogen Cat. No. 11995).
- Fetal bovine serum (FBS) (Cat. No. TM999-500) Note: FBS does not need to be heat-inactivated.
- 200 mM L-Glutamine (Sigma Cat. No. G7513)
- Solution of 10,000 units/ml Penicillin G sodium and 10,000 µg/ml Streptomycin sulphate (Sigma Cat. No. P0781)
- Complete Medium: DMEM supplemented with 100 units/ml Penicillin G Sodium, 100 µg/ml streptomycin and 10% fetal bovine serum (FBS)
- Puromycin (Cat. No. C021)
- Polybrene (Hexadimethrine Bromide; Cat. No. G062).
- Trypsin-EDTA (Trypsin; Sigma Cat. No. T3924)
- Dulbecco's Phosphate Buffered Saline (DPBS; VWR Cat. No. 82020-066)
- Tissue culture plates and flasks

Storage

- 293T cells in Liquid Nitrogen.
- Lentifectin™ at 4°C.
- All other components at -20°C.
- Spin briefly to recover contents and avoid repeated freeze-thaw cycles.

Protocol

B. Subcloning Target Sequences into iLenti Vector

1. Resuspend each target oligonucleotide in ddH₂O to a concentration of 100 μM.
2. Mix the sense and antisense oligos at a 1:1 ratio, resulting in 50 μM of ds oligo (assuming 100% annealing efficiency).
3. Using a PCR thermocycler, perform oligo annealing using the following program:

Table II. Thermocycler Conditions

Process	Temperature	Time
Denaturation	95°C	30 seconds
Annealing	72°C	2 minutes
Annealing	37°C	2 minutes
Annealing	25°C	2 minutes
Storage	0°C (On Ice)	Variable

The annealed oligonucleotide is now ready for ligation into the iLenti™ vector. Alternatively, the double stranded oligonucleotide can be stored at -20°C until needed.

4. Set up the following ligation reaction:

Table III. Ligation of siRNA Target into the iLenti™ Vector

Reagent	Volume
BbsI Linearized Vector	4 μl
Annealed Oligonucleotides	3 μl
5x DNA Ligase Buffer	2 μl
T4 DNA Ligase	1 μl
Total Volume	10 μl

Mix gently by pipetting up and down, followed by incubation at room temperature for 1-2 hours. **Note:** Temperatures greater than 25°C may negatively affect ligation efficiency.

5. Transform 3-5 μl of ligation product (above) with 50 μl standard DH5a competent cells. **Note:** Ensure that bacterial strains are authentic DH5a competent cells. Other strains of competent cells may negatively affect lentiviral titre or compromise lentiviral particle production altogether.
6. Following recovery, plate all cells on LB plates with 50 μg/ml Kanamycin and incubate overnight at 37°C.

Protocol

C. Identification of iLenti Clones

1. Randomly pick 10 well separated colonies from a LB plate and inoculate the colonies in 5ml of LB Broth with 50 µg/ml Kanamycin at 37°C overnight.
2. Extract DNA using a Mini-preparation kit.
3. Perform an EcoRI digestion of mini-prepared DNA to screen for recombinant colony. **Note:** *The parental iLenti™ vector has two EcoRI sites, one of which is located between the two BbsI sites. Digestion of parental iLenti-siRNA-GFP plasmid would thus produce two fragments of 1.6 kb and 7.4 kb in size (the iLenti-siRNA plasmid resulting in fragments of 0.8 kb and 7.4 kb). Ligation of siRNA target oligos into the iLenti™ vector will result in an iLenti-siRNA-GFP vector with a single EcoRI site, leading to a linearized vector of 9.0kb (8.2kb for iLenti-siRNA) after EcoRI digestion . The identified recombinant clones can be sequence-confirmed using the primers that are included in the kit for target siRNA sequence accuracy. Alternatively, if your insert happens to contain an EcoRI site the same principle can be applied with a Sall digestion, with parental having bands of 1.8kb and 7.3kb and iLenti -siRNA-GFP vector with insert being linearized 9.0kb.*
4. Perform a Maxi DNA preparation of recombinant iLenti™ clone for either target gene knockdown by direct transfection or for lentivirus production.

D. Lentiviral Particle Production

Currently, the most efficient and widely used protocol for producing high-titre lentiviral particles is based on transient co-transfection of a Lentiviral construct and structural protein plasmids in the packaging 293T cells. Following co-transfections in packaging cells, the highly-efficient hybrid CMV/5'LTR (or RSV/5'LTR) promoter from the expression construct drives the expression construct transcript containing all the functional elements (i.e., Psi, RRE, and cPPT) required for efficient packaging. The expression construct transcript is then efficiently packaged into VSV-G pseudotyped viral particles along with other structural proteins expressed from separate plasmids (all included in packaging mix). Viral particles can thus be used to transduce both dividing and non-dividing cells through VSV-G protein, which mediates viral entry through lipid binding and plasma membrane fusion (Burns, 1993).

Protocol

E. 293T Cells

The 293T cell line is widely used for optimal lentivirus production (Naldini et al., 1996). The health of 293T cells at the time of transfection is a critical factor for the success of lentivirus production. The use of “unhealthy” cells will negatively affect the transfection efficiency, resulting in low titre lentiviral stocks. For optimal lentivirus production, follow the guidelines below to culture 293T cells before use in transfection:

- Make sure that cells possess greater than 90% viability.
- Subculture and maintain cells in complete medium containing 0.1mM MEM Non-Essential Amino Acids, 4mM L-Glutamine, 1mM sodium pyruvate, and 10% FBS.
- Do not allow cells to overgrow before passaging.
- Use cells that have been subcultured for **less than 16 passages**.

F. Transfection Procedure

DAY 1:

1. In the afternoon, seed $\sim 1.2 \times 10^7$ 293T cells in a 10 cm dish.

DAY 2: (Carry out steps 2 - 6 in the morning on the day of transfection)

2. Check to make sure the cells are 70-80% confluent.
3. **For each 10 cm dish** prepare the transfection complex as follows:
 - a) **Solution A:** Dilute 20 μ g DNA plasmids (10 μ g expression vector and 10 μ g of **abm**'s Second Generation (LV003) or Third Generation (LV053) Packaging Mix) in 1 mL serum-free, antibiotic-free medium.
 - Solution B:** Dilute 80 μ L of LentiFectin™ Transfection reagent (G074) in 1 mL serum-free, antibiotic-free medium.
 - b) Incubate both solutions at room temperature for 5 minutes.
 - c) Mix Solutions A and B together well and incubate at room temperature for 20 minutes. This will create the transfection complex.
4. Add 4.5 mL serum-free medium to the transfection complex.
5. Remove the medium from the cells in the 10 cm dish.
6. Add the complete transfection complex from step 4 to the cells and incubate at 37°C for 5-8 hours. Avoid dislodging the cells by gently adding the mixture against the side wall of the dish.
7. Add 0.65 mL FBS to the 10 cm dish and incubate at 37°C overnight.

Protocol

DAY 3:

8. Remove the transfection medium from the cells.
9. Add 10 mL complete culture medium to the cells.
10. Incubate at 37°C for 24 hours.

DAY 4 (Harvest):

11. Collect the supernatant medium from the culture dish.
12. Centrifuge the supernatant at 3000 rpm for 15 minutes at 4°C to pellet cell debris.
13. Transfer the cleared supernatant to a fresh tube. Filter the cleared supernatant with a low-protein binding 0.45 µM sterile filter.
14. The viral titer of the first harvest is approximately 10⁶ IU/mL. The filtered supernatant will be ready for In vitro infections or further concentration and/or purification. Alternatively, it can be stored at -80°C as viral stock for future applications. Aliquotted volumes are preferred for long term storage to reduce the loss of viral titer through multiple freeze-thaw cycles.
15. A second harvest can be carried out by adding 10 mL of complete medium to the cells after the first harvest and incubating at 37°C for a further 24 hours. The first harvest can be stored at 4°C overnight to allow the second harvest to be added to it the following day (freezing the supernatant would result in a greater loss of titer).
16. Collect the second supernatant on Day 5 (as in steps 11-13) and combine this with the first harvest.

Note: Expression of the VSVG glycoprotein causes 293T cells to fuse, resulting in the appearance of large, multinucleated cells known as syncytia. This morphological change is normal and does not affect the production of the lentivirus.

17. For viral titers that are 10⁶ IU/mL and higher, you can quickly and easily titer your virus preparation using the qPCR Lentivirus Titer Kit (LV900) available from **abm**. In addition, our Ultra-Pure Lentiviral Purification Kit (LV998) will allow you to concentrate the virus to a higher titer if desired.

Protocol

G. Concentrating Virus

There are many protocols that have been established to concentrate VSV-G pseudotyped lentiviruses without significantly affecting their ability to transduce target cells. These include ultracentrifugation (Yee, 1999), filter-based ion exchange chromatography (Ultra-Pure Cat. No. LV998), and size exclusion chromatography (Speedy Lentivirus Purification Cat. No. LV999). However, we would strongly recommend using **abm**'s Ultra-Pure Lentivirus Purification Kit (Cat. No. LV998) for iLenti-siRNA vector concentration and purification, based on our in-house testing data.

H. Long Term Storage

Viral stocks stored at -80°C should be stable for at least one year. Repeated freeze/thaw cycles will result in a loss of viral titre (based on our in-house data, each freeze/thaw will lead to a 25% loss in titre).

I. Viral Titre Assays

It is useful to titre the viral supernatant before proceeding with the transduction experiments for the following reasons:

- To ensure that viral stock is viable.
- To determine the percentage of target cells that can be transduced with the pseudoviral stock.
- To control the number of copies of viral constructs per target cell.

The commonly used protocol for measuring relative viral titres uses a positive control expression plasmid (i.e. GFP mixed with expression construct) as an internal control at a ratio of 1:100 and is packaged into pseudoviral particles. In an alternative approach, the GFP control plasmid can be packaged separately but in parallel with your construct, as an external control. In this scenario, the control plasmid can be used to check and optimize the transfection/packaging steps (see transfection procedure). Recently, other *in vitro* protocols including qRCR and HIV p24 protein-based ELISA have been developed for quick assays.

To determine the relative titre, transduce a target cell line, like MDA-MB-468, in the presence of Polybrene (2 µg/ml) for 12-16 hrs, and then count the number of cells expressing GFP either by fluorescence microscopy or FACS.

Protocol

1. For each viral stock, plate MDA-MB-468 cells one day prior to viral infection in a 24-well plate at a density of 0.6×10^5 cells per well. Add 1 ml of complete DMEM medium (with serum and antibiotics) and incubate cells at 37°C with 5% CO₂ overnight. **Note:** *It is possible to use bigger culture dishes for transduction, especially when a large number of cells is needed for FACS analysis. In this case, the amount of cells should be adjusted based on the growth area of the dish.*
2. Prepare complete D-MEM medium plus 10% FBS with Polybrene to a final concentration of 2 µg/ml. **Note:** *Polybrene is a polycation that neutralizes charge interactions to increase binding between the pseudoviral capsid and the cellular membrane. The optimal concentration of Polybrene depends on cell type and may need to be empirically determined (usually in the range of 1–8 µg/ml). Excessive exposure to Polybrene (>12 hr) can be toxic to some cells.*
3. Remove culture medium and replace with 0.5 ml of complete DMEM medium with 10% serum and Polybrene (from Step 2). For each viral stock, use three wells. Infect MDA-MB-468 cells by adding 1 µl of viral stock into the first well (dilution factor of 500), 10 µl of viral stock into the second well (dilution factor of 50), and 100 µl of viral stock into the last well (dilution factor of 5). For controls, add 0.5 ml of DMEM medium with Polybrene (from Step 2). Incubate at 37°C with 5% CO₂ overnight.
4. Remove culture medium and replace with 1 ml of complete DMEM medium (without Polybrene). Incubate the cells at 37°C with 5% CO₂ overnight.
5. The following day, split the cells 1:3 to 1:5, if necessary, depending on the growth rate of cells. Incubate in complete DMEM for an additional 24-48 hours.
6. Count the fraction of fluorescent cells by FACS analysis. You may also count the GFP positive cells under a fluorescent microscope, but the results may be less accurate due to inconsistencies in counting methods. Use an average of the fraction of GFP⁺ cells in 5-10 random fields to estimate the overall percentage of GFP⁺ cells on the plate. Multiply the number of infected cells by 1.5×10^5 (in this example, the expected number of MDA-MB-468 cells on the plate at the moment of infection) and by the corresponding dilution factor, then divide by 0.5 ml to determine the relative titre of the virus in the supernatant. Alternatively, the viral titre can be estimated by real time PCR using ABM's Lentiviral qPCR Titre Kit (Cat. No. LV500) or p24-based ELISA titre kit (Cat. No. LV501).

J. Transduction Procedure

The following information should be considered before attempting to transduce your target cells with a lentiviral infection method:

- The transduction efficiency of target cells varies significantly under different experimental conditions, including virus concentration, exposure time to virus, and growth area of cells. To determine the viral concentration required to provide the desired multiplicity of infection (MOI) for your target cells, perform several transductions with different concentrations of viral particles containing GFP control plasmid. Results from these test transductions should be used to determine an optimal concentration that yields the highest percentage of infected cells.
- Recombinant gene expression can be measured directly 48 - 72 hours after transduction ("transient transduction"), but selecting stably transduced cells will require additional time after transduction. The decision to use "transiently transduced" cells or selected stable cells will depend on the nature of your target cells, biological assay, and transduction efficiency. For efficient transducible cells (e.g. 293, HT1080, HeLa, MDA-MB-468 cells, etc), most biological assays can be performed following transient transduction. However, for "difficult-to-transduce" cells, it is desirable to select the clones that stably express the lentivector construct for experimental assays.

The following provides general guidelines as a starting point for determining optimal conditions for target cell transduction:

1. Plate target cells in a 24-well plate 24 hours prior to viral infection at a density of 0.5×10^5 cells per well. Add 0.5 ml of complete optimal medium (with serum and antibiotics if required) and incubate cells at 37°C with 5% CO₂ overnight. *Note: It is possible to use other plate formats for transduction. In this case, the amount of cells should be adjusted depending on the growth area of the well/plate.*
2. Prepare a mixture of complete media with Polybrene at a concentration of 2 µg/ml. Remove media from the wells and replace with 0.5 ml of the Polybrene/media mixture per well (for 24-well plate).
3. Infect target cells by adding several different amounts of viral stock (example: 1 µl, 5 µl, 10 µl, and 100 µl of virus). In addition, include a transduction well with GFP positive control virus and other appropriate positive and negative control viral constructs. Incubate cells at 37°C with 5% CO₂ overnight.

Protocol

4. Remove the culture medium and replace with 1ml of complete medium. Incubate cells at 37°C with 5% CO₂ overnight.
5. The following day, split the cells 1:3 to 1:5, depending on the growth rate of your target cells, and continue incubating for 48 hours in complete DMEM.
6. The infected target cells can be either analyzed for transient expression or selected for stable expression using appropriate selection markers at a minimum concentration as determined by a killing curve.

For a troubleshooting guide, please refer to the table provided on the following page.

Protocol

Problem	Possible Cause	Solution
No Viral Particles	Lenti-III-GFP DNA modified (e.g. acetylation or methylation).	Re-transform plasmid into an authentic DH5a.
Low Viral Titre	Low transfection efficiency: -poor quality DNA. -low 293T viability. -transfection media containing antibiotics and serum.	-Purify DNA with an endotoxin-free Maxi column. -Use 293T cells under passage 16. -Reduce transfection antibiotic or serum.
	Low transfection efficiency.	Optimize calcium transfection procedure.
	Insufficient DNA used for transfection.	Use 30-50 µg of expression vector and 30-50 µg of packaging mix.
	293T cell density too low.	Optimal cell density is 90-95%.
	Viral supernatant harvested too early.	Optimal viral titres can be collected 48-72 hours post-transfection.
	Viral supernatant subjected to multiple freeze-thaw cycles.	Each freeze/thaw cycle can lose 25% of the titre. Make aliquots for long-term storage.
	Polybrene not used during transduction.	Transduce cells in the presence of polybrene.
No Transgene Expression	Promoter silencing.	Lentiviral vector may integrate into a chromosomal region that silences the promoter. Screen multiple antibiotic-resistant clones and select the one with the highest expression levels.
	MOI too low.	Use maximum MOI for cell transduction. This is very critical for Tet-expression vectors.
	Viral stocks stored incorrectly.	Aliquot and store at -80°C. Avoid freeze/thaw cycles.
	Target cells not transducible with lentiviral vectors.	Transduce target cells in the presence of polybrene.
	Antibiotic concentration too high.	Determine antibiotic sensitivity of target cells by performing a killing curve. Use minimum antibiotic concentration required.
	Cells harvested too early for assay.	Perform expression assay 3-4 days post-transduction and induction to allow the accumulation of expressed protein.
Cytotoxic Effects of Target Cells	Large volume of viral supernatant used for transduction.	Dilute viral supernatant 1:2 to 1:3 during transduction.
	Polybrene concentration too high.	Use less or omit polybrene during transduction.
	Antibiotic concentration too high.	Use minimum antibiotics for effective selection.
	Gene of interest toxic to cells.	Try a different cell line.

References

- Brummelkamp TR, Bernards, R, Agami R.** A system for stable expression of short interfering RNAs in mammalian cells. *Science* 2002, 296(5567):550-553.
- Buchschacher, G. L., Jr., and Wong-Staal, F.** (2000) Development of Lentiviral Vectors for Gene Therapy for Human Diseases. *Blood* 95, 2499-2504
- Burns, J. C., Friedmann, T., Driever, W., Burrascano, M., and Yee, J.K.** (1993) Vesicular Stomatitis Virus G Pseudotyped Retroviral Vectors: Concentration to a Very High Titer and Efficient Gene Transfer into Mammalian and Nonmammalian Cells. *Proc. Natl. Acad. Sci. USA* 90, 8033-8037
- Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., and Naldini, L.** (1998) A Third-Generation Lentivirus Vector with a Conditional Packaging System. *J. Virol.* 72, 8463-8471.
- Elbashir SM, Harborth, Lendeckel W, Yalcin A, Weber K, Tuschli T.** Duplexes of 21-nucleotide RNAs mediated RNA interference in cultured mammalian cells. *Nature* 2001, 411(6836):494-498.
- Emi, N., Friedmann, T., and Yee, J.-K.** (1991) Pseudotype Formation of Murine Leukemia Virus with the G Protein of Vesicular Stomatitis Virus. *J. Virol.* 65, 1202-1207.
- Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE and Mello CC** (1998) Potent and specific gene genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature* 1998,391:806-811.
- Grünweller A, Hartmann RK.** RNA interference as a gene-specific approach for molecular medicine. *Curr Med Chem.* 2005;12(26):3143-61. Review.
- Hammond SM, Bernstein E, Beach D, Hannon GJ.** An RNA-directed nuclease mediates post-transcriptional gene silencing in *Drosophila* cells. *Nature* 2000, 404:293-296.
- Hawkins PG, Morris KV.** RNA and transcriptional modulation of gene expression. *Cell Cycle.* 2008 Mar;7(5):602-7. Epub 2007 Dec 29.
- Kim DH, Behlke MA, Rose SD, Chang MI, Choi S, Rossi J.** Synthetic dsRNA dicer substrates enhance RNAi potency and efficacy. *Nature Biotechnology* 2005, 23(2)225-226.

References

- Lewis, P. F., and Emerman, M.** (1994) Passage Through Mitosis is Required for Oncoretroviruses but not for the Human Immunodeficiency Virus. *J. Virol.* 68, 510-516.
- Luciw, P. A.** (1996) in *Fields Virology* (Fields, B. N., Knipe, D. M., Howley, P. M., Chanock, R. M., J. L., Monath, T. P., Roizman, B., and Straus, S. E., eds), 3rd Ed., pp. 1881-1975, Lippincott-Raven Publishers, Philadelphia, PA.
- McManus MT and Sharp PA.** Gene silencing in mammals in small interfering RNAs. *Nat Rev Genet* 2002, 3:737-747.
- Naldini, L.** (1998) Lentiviruses as Gene Transfer Agents for Delivery to Non-dividing Cells. *Curr. Opin. Biotechnol.* 9, 457-463.
- Naldini, L.** (1999) in *The Development of Human Gene Therapy* (Friedmann, T., ed), pp. 47-60, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- Sambrook, J. & Russell, D.W.** (2001) *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).
- Shin KJ, Wall EA, Zavzavadjian JR, Stntat LA, Liu J, Hwang JI, Rebres R, Roach T, Seaman W, Simonn MI, Frazer ID.** A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression. *Proc Natl Acad Sci USA* 2006, 103(37):13759-13764.
- Wiznerowicz M, Trono D.** Conditional suppression of cellular genes. *J Virol* 2003, 77 16):8957-8961.
- Yee, J.-K., Miyanochara, A., LaPorte, P., Bouic, K., Burns, J. C., and Friedmann, T.** (1994) A General Method for the Generation of High-Titer, Pantropic Retroviral Vectors: Highly Efficient Infection of Primary Hepatocytes. *Proc. Natl. Acad. Sci. USA* 91, 9564-9568.
- Yee, J. K.** (1999) in *The Development of Human Gene Therapy* (Friedmann, T., ed), pp. 21-45, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- Yee, J. K., Moores, J. C., Jolly, D. J., Wolff, J. A., Respass, J. G., and Friedmann, T.** (1987) Gene Expression from Transcriptionally Disabled Retroviral Vectors. *Proc. Natl. Acad. Sci. USA* 84, 5197-5201.

Contact Information

Applied Biological Materials Inc.

Website:

www.abmGood.com

Phone:

(8:30am-4:30pm PST M-F)

Toll Free: 1-866-757-2414

Local: (604) 247-2416

Fax: (604) 247-2414 (24Hr.)

Address:

Suite #8-13520 Crestwood Place

Richmond, BC

Canada V6V 2G2

Email:

General Information:

info@abmGood.com

Order Products:

order@abmGood.com

Technical Support:

technical@abmGood.com

Business Development:

bd@abmGood.com

Distributors

North America

Canada

Applied Biological Materials Inc.

Tel: (604) 247-2416 / 1-866-757-2414

Fax: (604) 247-2414

www.abmGood.com

United States

Applied Biological Materials Inc.

Tel: (604) 247-2416 / 1-866-757-2414

Fax: (604) 247-2414

www.abmGood.com

Mexico

Quimica Lavoisier S.A. de C.V.

Tel: 52-333-848-8484

Email: informes@lavoisier.com.mx

www.lavoisier.com.mx

International

Australia

Biosensis Pty Ltd.

Tel: +61 43 166 5519

Email: sales@biosensis.com

www.biosensis.com

Belgium

Gentaur

Tel: 32 2 732 5688

Email: ea@gentaur.com

www.gentaur.com

France

Gentaur

Tel: 01 43 25 01 50

Email: ea@gentaur.com

www.gentaur.com

Germany

BioCat GmbH

Tel: +49 (0) 6221-714-1516

Email: info@biocat.com

www.biocat.com

India

G Biosciences

Tel: 0120-432-3330

Email: rohit@gbiosciences.com

www.GBiosciences.com

Israel

BioConsult

Tel: 972-(0)2-566-7043

Email: sales@bioconsult.co.il

www.bioconsult.co.il

Italy

MICROTECH s.r.l.

Tel: +39-0816107435

Email: microtech@microtech.eu

www.microtech.eu

Japan

Cosmo Bio Co. Ltd.

Tel: 03-5632-9610/9620

Email: mail@cosmobio.co.jp

www.cosmobio.co.jp

Singapore

Bio-REV PTE

Tel: (65) 6273-3022

Email: allan@bio-rev.com

bio-rev.com

South Korea

CMI Biotech

Tel: 02 444 7101

Email: cmibio@cmibio.com

www.cmibio.com

Taiwan

Interlab Co. Ltd.

Tel: +886-2-2736-7100

Email: service@interlab.com.tw

www.interlab.com.tw

United Kingdom

NBS Biologicals Ltd.

Tel: +44 (0)1480 433875

Email: info@nbsbio.co.uk

www.nbsbio.co.uk

The Source for

any Antibody, siRNA, and Viral Vector

The Depot for

PCR, qPCR, and Transfection Reagents

